Effective adjuvant therapy for severe sepsis and shock;Adjuvante behandelingen voor sepsis en shock: Welke zijn effectief?

Nederlands Tijdschrift voor Geneeskunde

Volumn 145, Issue 36, 2001, Pages 1718-1722

  Groeneveld, A B J ^a   Beishuizen, A ^a   Appelmelk, B J ^a   Girbes, A R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CASPASE INHIBITOR; HEPARIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MEDICAL DECISION MAKING; REVIEW; SEPSIS; SHOCK; TREATMENT PLANNING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BLOOD PROTEINS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEPARIN; HUMANS; HYDROCORTISONE; INTENSIVE CARE; MEMBRANE PROTEINS; PROTEIN C; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, INTERLEUKIN; SEPSIS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035828457     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Prediction of shock in febrile medical patients with a clinical infection
2. Clinical trials of mediator-directed therapy in sepsis: What have we learned?
3. Efficacy and safety of recombinant human activated protein C for severe sepsis
4. Prediction of microbial infection and mortality in medical patients with fever: Plasma procalcitonin, neutrophilic elastase-alpha1-antitrypsin, and lactoferrin compared with clinical variables
5. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia
6. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
7. Evolution of an immune suppressive macrophage phenotype as a product of P38 MAPK activation in polymicrobial sepsis
8. Adrenal dysfunction in critical illness: A clinical entity that requires treatment?
9. Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome
10. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients
11. The inflammatory effect of coagulation and the antiinflammatory effect of anticoagulation in sepsis and shock
12. Relatieve bijnierschorsinsufficiëntie bij sepsis, gediagnosticeerd en behandeld door hydrocortisonsuppletie
13. Suppletie met corticosteroïden bij ernstig zieke patiënten
14. Recombinant bactericidal/permeability-increasing protein (rBPI(21)) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
15. Effects of the combination of hydrocortisone (HC) fludro-cortisone (FC) on mortality in septic shock
16. Treatment of severe sepsis with C1 inhibitor
17. Inhibition of p38 mitogen activated protein kinase: A novel strategy in sepsis?
18. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein kinase inhibitor, in healthy human volunteers
19. Treatment with afelimomab in patients with severe sepsis is associated with improved IC-free days
20. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis
21. Heparin blunts endotoxin-induced coagulation activation
22. The effect of glutathione and N-acetylcysteine on lipoperoxidative damage in patients with early septic shock
23. Methylene blue increases myocardial function in septic shock
24. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
25. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia
26. An open-label dose escalation study of the nitric oxide synthase inhibitor. N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock
27. The effects of ibuprofen on the physiology and survival of patients with sepsis
28. Clinical trial results with antithrombin III in sepsis
29. Protective effect of tyrphostin AG-556 on shock induced by endotoxin or gram positive bacteria
30. Poly(ADP-ribose) synthetase as a novel therapeutic target for circulatory shock
31. Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte
32. Soluble glucan protects against endotoxin shock in the rat: The role of the scavenger receptor
33. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C
34. Protein C replacement in severe meningococcemia: Rationale and clinical experience
35. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
36. Does heparin improve survival in experimental porcine gram-negative septic shock?
37. Effects of nonanticoagulant heparin on cardiovascular and hepatocellular function after hemorrhagic shock
38. Effects of low molecular weight heparin, alone or combined with antithrombin III, on mortality, fibrin deposits and hemostatic parameters in endotoxin-induced disseminated intravascular coagulation in rabbits
39. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture
40. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
41. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient